On August 2, 2022 iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, reported that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Conference titled: "IOs Wide Open – Opportunities and Challenges in Immuno-Oncology" on Tuesday, August 9, 2022 at 8:00 a.m. ET (Press release, iTeos Therapeutics, AUG 2, 2022, View Source [SID1234617292]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the events will be available on the Investors section of the company’s website at View Source An archived replay will be available for approximately 30 days following the presentation.